Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LANDI-PED study of AOP Landiolol for supraventricular tachycardia in pediatric patients
2015-001129-17Phase 3Completed
- Sponsor
- AOP Health
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of landiolol in supraventricular tachycardia (SVT) and Atrial fibrillation (AFib), sponsored by AOP Health. Primary endpoint: Cardioversion to sinus rhythm. Started May 2017; status: completed.
02
Drugs
landiolol
03
Conditions
supraventricular tachycardia (SVT)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2015-001129-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001129-17.